ith increased travel globally, more women travel while breastfeeding their infants as well as during pregnancy. The transfer of drugs and chemicals into human milk differs from transfer via umbilical cord during pregnancy. Because there is little evidencebased literature on recommendations for breastfeeding travelers, we review factors that influence drug passage into breast milk and available safety data on common medications that may be encountered by breastfeeding travelers. Biologic and immunologic events in the mother may affect the breastfeeding infant. We review those that are relevant to the breastfeeding woman who is preparing to travel. We also review the use of vaccines in breastfeeding women and the mechanisms by which they could affect the infant.
W ith increased travel globally, more women travel while breastfeeding their infants as well as during pregnancy. The transfer of drugs and chemicals into human milk differs from transfer via umbilical cord during pregnancy. Because there is little evidencebased literature on recommendations for breastfeeding travelers, we review factors that influence drug passage into breast milk and available safety data on common medications that may be encountered by breastfeeding travelers. Biologic and immunologic events in the mother may affect the breastfeeding infant. We review those that are relevant to the breastfeeding woman who is preparing to travel. We also review the use of vaccines in breastfeeding women and the mechanisms by which they could affect the infant.
Breastfeeding: Physiology
Physiologic changes that occur with breastfeeding involve the hormones oxytocin and prolactin. The hyperplasia of milk ducts and production of immunologically rich human milk occur through the feedback mechanism of suckling. Changes to the mother's immune system following vaccine administration should not differ from the non-breastfeeding state, though little research has been directed to this question. Breast milk does not adversely impact the response to vaccines administered directly to the infant. 1, 2 Specific antibody responses to travel-related vaccines have not been studied in nursing mothers.
Maternal plasma volume expands by 50% through pregnancy and returns to normal level in most women by 8 weeks postpartum. 3 This increases the volume of distribution of drugs administered, related to the amount of protein binding of the given compound.
Passage of Drugs into Breast Milk
Although most medications transfer into human milk, many are found at low concentrations in breast milk and are relatively safe for the infant. The clinician should consider the risk of the drug versus the benefit of breastfeeding for the infant. Maternal, drug, and infant factors influence the amount of drug available to the nursing infant.
The factors influencing drug transfer from maternal circulation into breast milk include ionization, lipid solubility, molecular weight, half-life of drug, fat content of milk, maternal plasma protein binding, and blood level attained in the maternal circulation. 4 Plasma protein binding affects the degree of drug penetration into breast milk. Although the protein-bound fraction remains in the maternal circulation, unbound drug can be transferred into human milk. Thus, the higher the percentage of protein binding, the less likely the drug will enter maternal milk.
Most drugs enter human milk as a result of equilibrium forces that lead to passive diffusion across the alveolar bilayer membranes and into the milk compartment. Low molecular weight drugs (<200 kd) transfer easily into human milk, but high molecular weight drugs are virtually excluded from human milk. 5, 6 Once drugs enter breast milk, close equilibrium is maintained between the plasma and milk compartments with diffusion into and out of milk as a function primarily of the maternal plasma level. 7 Drugs with greater lipidsolubility diffuse across the membranes into breast milk and result in greater transfer into breast milk. The rate of transfer of lipid-soluble drugs into breast milk is generally quicker than water-soluble drugs that must pass through pores to cross cell membranes. 5 Colostrum (milk formed within the first few days of lactation) has lower fat content than mature milk. 8 Thus, drugs with high lipid solubility achieve a greater concentration in mature milk. As the mother's serum concentration drops from metabolism and excretion of drug, the concentration of drug in the breast milk may redistribute back in the mother's bloodstream. Maternal plasma pH is 7.4 but the mean pH of breast milk is 7.2. 9 Drugs that are weak bases are un-ionized in the maternal circulation and can easily pass into breast milk; however, upon entrance into breast milk, they may become iontrapped in breast milk. On the other hand, drugs that are weak acids will exhibit minimal diffusion into breast milk. Drugs with longer half-lives are more likely to accumulate in the mother and infant than agents with shorter half-lives. 6 There are different methods for estimating the potential amount of drug that an infant obtains through breastfeeding. 6, 8 The milk-to-plasma (M/P) ratio provides an estimate of the drug's distribution between maternal milk and plasma. Generally, the M/P ratio correlates directly with the amount of drug found in breast milk. An M/P ratio lower than 1.0 suggests that little drug will be transferred into breast milk. Unfortunately, the M/P ratio may be misleading as it is subject to variability. 9 Calculating the relative infant dose (RID) provides an estimate of the weightnormalized dose relative to the mother's dose. 6, 10 The RID is calculated as follows:
The infant dose is calculated from the drug concentration in the breast milk and multiplied by the total volume of milk that is ingested by the infant. The RID is expressed as a percentage of the maternal dose. Generally, the RID should not exceed 10% of the maternal dose; for pre-term infants, the RID should be less than 10% due to the infant's immature hepatic and renal systems.
Oral bioavailability of the drug is another important factor to consider in both mother and infant. 6 As drug enters breast milk and is ingested, it must pass through the infant's gastrointestinal (GI) tract before absorption. Some drugs are destroyed within the GI tract and thus are not bioavailable in the infant 11 ; drugs that are not destroyed in the infant's GI tract benefit from a short gastric emptying time which reduces the exposure time of the drug and minimizes the potential of an adverse reaction. One must also consider the frequency of feedings and volume of breast milk ingested when considering bioavailability. Of note, variations occur in an infant's ability to metabolize, excrete, and respond to medications (ie, idiosyncratic reactions, allergic sensitization). 10 Premature and fullterm infants may not have full renal and liver function and some infants have immature GI function. Thus, it is essential to evaluate the infant's ability to handle small amounts of medication before prescribing a medication for a breastfeeding woman.
Vaccines Used in Travelers
Vaccination during breastfeeding protects the mother from vaccine-preventable diseases, indirectly protects the infant by preventing maternal infection, and prevents infection in subsequent pregnancies. 1 Research is needed regarding possible changes in the immune response of breastfeeding women as for pregnant women. Additional questions relevant to vaccinating breastfeeding women are: (1) transfer of live microbes (viruses or bacteria); (2) transfer of specific antibodies that aid or block immunologic response in infant; and (3) transfer of chemicals used in the vaccines.
The major concern regarding live vaccines is that microbes, although attenuated, might pass through breast milk to an infant with little or no immunity. This is the case with smallpox, which can be associated with severe consequences. Among women immunized with rubella vaccine (RA27/3), >69% shed the virus in breast milk, which led to IgA antibodies to rubella in breast milk. 12 Animal and human studies suggest that IgA antibodies in mammary glands, colostrum, and breast milk are induced by specific antigens followed by migration of antigen-reactive precursor cells from intestinal and/or bronchial lymphoid tissues. 12 In 50% of the immunized women, rubella vaccine virus persisted in breast milk up to 10-17 days postimmunization. 13 Of breastfed infants, 56% had rubella virus from nasopharynx or throat (0% in non-breastfed infants) and 25% had transient seroconversion to rubella virus without clinical disease (0% in non-breastfed infants). 13 Therefore, breastfeeding is not a contraindication or precaution to rubella vaccination.
In a study of varicella vaccine, 12 postpartum women received varicella vaccine at least 6 weeks after delivery, and all seroconverted. 14 Over 200 samples of breast milk tested by polymerase chain reaction for varicella vaccine virus were negative, and all infants remained seronegative. 14 Although small, this study supports postpartum vaccination of susceptible women without interruption of breastfeeding.
The second concern is that antibody transferred via human milk may interfere with the infant's response to childhood immunizations, especially oral vaccines. Oral polio vaccines (live) administered to breastfed infants on day 3 of life were capable of producing infection in 57% of infants despite maternal antibodies in colostrum. 15 Antibodies in breast milk inhibited newborns' seroconversion following polio immunization. 16 This effect was temporary and it was considered unnecessary to withhold breastfeeding when administering oral polio vaccines to infants >6 weeks of age. 17 Moreover, antibody response following rubella vaccine in breastfed infants whose mothers received rubella vaccine postpartum was similar to those in formula-fed infants and infants of naturally immune mothers. 18 Hence, immunization with rubella in breastfeeding women does not suppress the immune response to rubella vaccine in the infant.
Antibody persistence in breast milk may vary depending on antibody type. Women vaccinated during pregnancy with pneumococcal and meningococcal polysaccharide vaccines had specific IgA type 6B antibodies in colostrum that fell to undetectable levels by 2 weeks, whereas type 19F antibodies were found in breast milk up to 5 months. 19 Because an insignificant amount of antibodies in breast milk pass from the GI tract into infant circulation, these antibodies do not suppress the infant immune response. 20, 21 Preservatives and other components of vaccines have caused concern over their potential effect on infants. Studies have assessed the effect of vaccine components (adjuvants, chemicals, preservatives, and additives) on infants, particularly that of thimerosol. Research has repeatedly refuted the association of adverse effects from thimerosol in vaccines administered directly to infants, 22 and the minute amounts that may possibly pass through breast milk should further reduce concern. Unfortunately, such concerns may lead to interruption of breastfeeding when the mother is immunized. The common Food and Drug Administration label ''because many drugs are excreted in human milk, caution should be exercised when administering vaccine to a nursing woman'' does little to reassure. Nonetheless, with the exception of smallpox vaccine, breastfeeding is not a contraindication to vaccination (Table 1) .
Drugs and Chemicals Used in Travelers
Drugs that breastfeeding travelers may encounter include anti-infectives, antimalarials, high-altitude medications, analgesics, antimotility drugs, and topical preparations. The following section will review available data regarding their safety in breastfeeding infants.
Anti-infectives
The most commonly prescribed anti-infectives in the pre-travel consultation are quinolones, macrolides, and occasionally sulfonamides, usually for self-treatment of travelers' diarrhea. Doxycycline, a tetracycline prescribed for chemoprophylaxis of malaria, is also frequently considered in the United States but the World Health Organization (WHO) considers it contraindicated for prophylaxis and treatment for breastfeeding women. 49 As early as 1947, sulfonamides were recognized to pass into milk and persist for days after drug cessation, although studies on sulfanilamide showed no toxic effects in babies. 50 Sulfonamides are generally compatible in breastfeeding but should be used with caution in infants with hyperbilirubinemia. 6 Sulfamethoxazole has a longer half-life than other sulfonamides, ranging from 8 hours in infants to 36 hours in neonates. 51 Sulfisoxazole appears to be the best choice within the drug class because less than 1% of the maternal dose is secreted into human milk. 6 Data regarding tetracycline transfer into human milk have demonstrated limited secretion into breast milk. For example, women taking 2 gm tetracycline daily demonstrated a blood level of 0.65-3.0 μg/mL, while breast milk level was 0.43-2.1 μg/mL. 52 Nursing infants absorbed only 1% of therapeutic dose and probably even less because of protein binding to calcium. 52 Doxycycline, a newer analog of tetracycline, binds less to calcium salts and its overall absorption may be higher than that of tetracycline. The RID of doxycycline would be <6% of the maternal weightadjusted dose. Harmful effects in breastfed infants have not yet been reported. Short-term use of doxycycline (3-4 wk) is not contraindicated in the United States (although contraindicated per WHO as noted above) but prolonged use is not advised. 6 On the other hand, quinolones were found in high levels in breast milk (ciprofloxacin, pefloxacin, ofloxacin); the breast milk ratio was >75% of serum levels at 2 hours after medication. 53 Because of concerns regarding arthropathy, at that time the authors recommended avoiding quinolones in lactating women. 53 More recently, inhalational and systemic anthrax cases led to the recommendation for initial treatment (including breastfeeding women) with intravenous ciprofloxacin or doxycycline plus one to two more antimicrobial agents. 54 According to the American Academy of Pediatrics (AAP), ciprofloxacin and tetracyclines are usually compatible with breastfeeding because the amounts absorbed by infants are small, but longterm safety is unknown. 55 Azithromycin concentration from the breast milk of a patient being treated with the medication and analyzed by chromatography with electrochemical detection was found to be time dependent; however, this may not be clinically significant 56 (Table 2) .
Antimalarials
Chloroquine is a small molecule, a base, that is 60-65% bound in plasma and is excreted in human milk. 69 -72 Current data suggest that chloroquine is compatible with breastfeeding. 72 Although adverse effects in breastfed infants have not been reported, close observation is recommended particularly for diarrhea, GI distress, and hypotension. 6 Hydroxychloroquine is a weak base and has a large volume of distribution, which suggests low transfer into milk. A dose of 800 mg hydroxychloroquine given to a woman resulted in 0.0003% of dose secreted in breast milk over 48 hours. 73 Although only a small amount of drug is secreted in breast milk, toxicities can occur with prolonged use (eg, retinal damage). Hydroxychloroquine is primarily metabolized to chloroquine and has a long half-life. 73 Because of its slow elimination rate, hydroxychloroquine can possibly accumulate to toxic amount, and daily hydroxychloroquine should be taken cautiously. 74 The AAP considers hydroxychloroquine to be generally compatible with breastfeeding.
There are no human data regarding the transfer of atovaquone and proguanil into breast milk. Malarone, which is a fixed combination of atovaquone and proguanil, is approved for use for treating pediatric patients ≥5 kg. The Centers for Disease Control and Prevention (CDC) recommends that mefloquine be used instead of Malarone in breastfeeding women whose infants weigh <5 kg. Mefloquine is secreted in small amounts into breast milk (approximately 3% of maternal dose). 6 Although no harmful effects have been reported with mefloquine, lactation should be discontinued if neuropsychiatric disturbance (change in sleep or behavior) is suspected in the child. There are no data on the transfer of primaquine into breast milk nor on its use in lactation. 6 Because of its known adverse effects, primaquine is contraindicated during lactation unless both the mother and the infant have documented normal G6PD levels 75 ( Table 3) .
Miscellaneous Oral Medications: High-altitude, Antimotility, Analgesic, Anti-inflammatory, and Sleep Aid
Medications to prevent or treat acute mountain sickness are sometimes prescribed in travelers, most commonly acetazolamide which is a weak acid. Because the pH of breast milk is usually lower than blood, the concentration is expected to be lower in breast milk than blood. When acetazolamide 500 mg bid was given to a nursing mother for 1 week, the infant's daily dose was measured at about 0.06% of the mother's dose. After adjustment for body weight, the infant's dose was 1/130 of mother's dose/kg body weight. 80 Nifedipine, sometimes used to prevent or treat highaltitude pulmonary edema, is 90% bound to plasma protein, thus only a small amount is available for transfer to milk. Assay of milk from a lactating woman taking nifedipine showed about 0.0027% of a 90 mg daily dose in milk, reaching peak within 1 hour. 81 Thus only an insignificant amount is transferred (<5% of a therapeutic dose); delaying breast feeding for 3-4 hours after taking the drug would further reduce the amount.
Dexamethasone is also used for high-altitude travel. No adverse effects have been reported with small amounts of corticosteroids in breast milk. 74 The AAP considered prednisone/prednisolone safe and compatible with breastfeeding. 55 A woman on highdose steroids can decrease the amount of steroid in milk by delaying breastfeeding for 4 hours after the dose.
Loperamide is used to treat symptoms of travelers' diarrhea. Samples from six lactating women had extremely small amounts of loperamide and loperamide oxide in plasma and even lower concentrations in breast milk (by radioimmunoassay). 82 A breastfed infant consuming 165 mL/kg of milk daily from a mother who ingests 4 mg bid would get 1/2000 of the therapeutic dose of loperamide and 1/8000 of the dose of loperamide oxide. 83 Analgesics and anti-inflammatory medications are commonly used by travelers. Aspirin is polar, is acidic, penetrates into breast milk poorly, and is eliminated slowly. 84 Measurement of salicylate excretion by chromatography in nursing mothers showed that it was detectable in milk within 1 hour and peaked in 2-6 hours, suggesting that single doses of aspirin would not lead to clinically significant levels in milk, but repeated doses may be significant due to slow elimination. 85 Breastfed neonates whose mothers take aspirin have been found to have substantial serum salicylate levels; concerns include metabolic acidosis, bleeding, effect on pulmonary circulation, and Reye syndrome. 74 A single dose of 450-650 mg delivers 0.1-21% to the infant over a 24-hour period. 86 AAP cautions the use of aspirin in breastfeeding mothers and recommends avoidance of large doses. 55 Ibuprofen is highly protein bound, a weak acid, present in ionized form in greater proportion in plasma than in breast milk; no measurable concentration of ibuprofen was detected in the milk of breastfeeding women taking ibuprofen 400 mg every 6 hours. 87 Trace amounts of non-steroidal anti-inflammatory drugs (NSAIDs), which displace bilirubin and lead to increased risk of kernicterus, have been reported in milk. Therefore, NSAIDs are contraindicated in woman breastfeeding a jaundiced neonate. 74 Acetaminophen is an alternative analgesic.
In contrast to aspirin, acetaminophen is hydrophilic and a relatively neutral/weak acid. Acetaminophen is rapidly absorbed and distributed to milk; assay by liquid chromatography showed it to be present in milk by 15 minutes after an oral dose, peak between 1 and 2 hours, with none detected after 12 hours. 86 Codeine is found in higher concentration in milk, being a weak base, highly lipophilic, and has low plasma protein binding. 84 Some travelers treat water with iodides and a very small amount is excreted in milk. 50 A nursing mother who used povidone-iodine vaginal gel for 6 days (50 mg iodine) noted an iodine odor in her 7 1 / 2 -month-old breastfed infant 2 days later. The infant's serum and urine iodine levels were elevated. 88 Iodine was absorbed through vaginal mucosa, concentrated in breast milk, and reached a level in breast milk eight times that of serum. 88 Acquired hypothyroidism has been reported in full-term and pre-term breastfed infants whose mothers had topical exposure to iodine. 89, 90 It appears prudent to avoid iodine preparations in breastfeeding travelers. Some travelers request sleep aids. Benzodiazepines are excreted in breast milk. 91 Zolpidem is an imidazopyridine derivative unrelated to benzodiazepine with hypnotic effect, rapid onset, short duration, and usually touted for no residual sleepiness. It has a rapid absorption and short half-life. Zolpidem is detected in breast milk 3 hours after a 20 mg dose at <0.02% of oral dose (milk/plasma ration of 0.13) primarily via passive diffusion. 91 No drug is detected in samples taken at 13 and 16 hours. 91 Finally, topical products such as N ,N -diethyl-mtoluamide (DEET) and sunscreen may be ingested by breastfeeding infants if they are applied on or near the breast. The infrequent cases of DEET toxicity have been associated with ingestion as well as inhalation and ocular exposure, 92 whereas sunscreens contain myriad chemicals that can potentially cause toxicity when ingested. Breastfeeding women should apply topical products such as repellents and sunscreens at a distance from the breast and wash their hands after their application to avoid ingestion by the nursing infant (Table 4) .
Advice and Precautions for Breastfeeding Travelers
Clinicians advising or treating breastfeeding travelers must balance a mother's health and a nursing infant's safety. Medications (ie, antimalarials) taken by breastfeeding mothers do not give protective drug levels in the infant. Administration of the same drugs to mother and breastfeeding infant does not lead to excessive drug level or toxicity in the infant. RID = relative infant dose; M/P = milk/plasma ratio; EPA = Environmental Protection Agency * This section summarizes key information and does not include all data on secretion of drug into breast milk.
Adequate hydration should be emphasized, especially for travel to high altitudes or hot environments. Breastfeeding travelers may be at greater risk of mosquito bites at night, if they get up frequently and leave mosquito netting to nurse or go to the bathroom, as was the case with pregnant women. 107 Increased attractiveness to mosquitoes, per se, has not been documented.
Empiric treatment of travelers' diarrhea is important. Many diseases are spread by fecal-oral route and careful hand washing (and avoidance of contamination of skin around breasts, nipples, and baby's mouth) is critical. Medications prescribed for travelers' diarrhea should be reviewed for excretion in breast milk and used accordingly. Breastfeeding travelers may need to pump milk if separated from the infant. Electric pumps need compatible electric current supply. Manual pumps are reliable, though more time-consuming to operate. Meticulous attention to the cleanliness of the breast pump and breast hygiene are important to avoid mastitis. The traveler should be advised of findings that suggest mastitis: fever, chills, flulike myalgia, and variable breast findings of an erythematous wedge or localized tenderness. Predisposing factors to development of this painful condition include engorgement, infrequent or disrupted feeding schedule, rapid weaning, maternal stress, and fatigue. Infection may or may not be associated with the inflammation. Treatment should be directed at the most common pathogen, Staphylococcus aureus. Methicillin-resistant S. aureus, to date, has rarely been reported as the cause. 108, 109 In addition, intertrigo on the under surface of the breast may occur in hot climates, necessitating antifungal treatment.
Milk storage and reliable refrigeration are also crucial considerations. If reliable storage and transport are unavailable, the traveler should discard the milk rather than risk feeding the infant the contaminated milk. The traveler should also be aware of cultural aspects and expectations of breastfeeding at the destination. Potential adjustments of feeding style in a culturally sensitive manner may be addressed at a pre-travel visit.
Conclusion
Breastfeeding women and their infants can travel safely, but need special attention to protect the infant. A critical goal is to maintain adequate hydration. Geographic areas where clean water and sanitation are lacking pose particular hurdles to any traveler and are especially difficult for the breastfeeding woman. Careful planning and assessment of local resources are important to preserve the health of infant and mother.
